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Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating
symptoms. For patients with moderate-to-severe COPD, long-acting bronchodilators are the mainstay of therapy; as
symptoms progress, guidelines recommend combining bronchodilators from different classes to improve efficacy.
Inhaled long-acting b2-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and
include formoterol and salmeterol. They improve lung function, symptoms of breathlessness and exercise limita-
tion, health-related quality of life, and may reduce the rate of exacerbations, although not all patients achieve clini-
cally meaningful improvements in symptoms or health related quality of life. In addition, LABAs have an acceptable
safety profile, and are not associated with an increased risk of respiratory mortality, although adverse effects such
as palpitations and tremor may limit the dose that can be tolerated.
Formoterol and salmeterol have 12-hour durations of action; however, sustained bronchodilation is desirable in
COPD. A LABA with a 24-hour duration of action could provide improvements in efficacy, compared with twice-
daily LABAs, and the once-daily dosing regimen could help improve compliance. It is also desirable that a new
LABA should demonstrate fast onset of action, and a safety profile at least comparable to existing LABAs.
A number of novel LABAs with once-daily profiles are in development which may be judged against these criteria.
Indacaterol, a LABA with a 24-hour duration of bronchodilation and fast onset of action, is the most advanced of
these. Preliminary results from large clinical trials suggest indacaterol improves lung function compared with pla-
cebo and other long-acting bronchodilators. Other LABAs with a 24-hour duration of bronchodilation include car-
moterol, vilanterol trifenatate and oldaterol, with early results indicating potential for once-daily dosing in humans.
The introduction of once-daily LABAs also provides the opportunity to develop combination inhalers of two or
more classes of once-daily long-acting bronchodilators, which may be advantageous for COPD patients through
simplification of treatment regimens as well as improvements in efficacy. Once-daily LABAs used both alone and in
combination with long-acting muscarinic antagonists represent a promising advance in the treatment of COPD,
and are likely to further improve outcomes for patients.
Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease characterized by increasing airflow lim-
itation and respiratory symptoms, often associated with
chronic comorbidities, leading to a significant burden
for the patient.
Specific pharmacological therapy for COPD helps to
prevent and control symptoms, reduce the frequency
and severity of exacerbations, improve health status and
improve exercise tolerance [1-3]. Inhaled bronchodila-
tors, such as b2-agonists and muscarinic antagonists,
improve lung function by altering airway smooth muscle
tone but also act on peripheral airways [4]. They reduce
air trapping and improve emptying of the lungs, thereby
reducing lung volumes, improving symptoms such as
breathlessness and increasing exercise capacity [1,5].
The present review focuses on the role and future of
long-acting b2-agonists (LABAs) in the management of
COPD, updating previously published reviews [6].
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b2-agonists
The principal action of b2-agonists is to relax airway
smooth muscle by stimulating b2-adrenergic receptors.
This increases the intracellular messenger cyclic AMP
that is responsible for the control of smooth muscle
tone [7]. Thus, activation of the b2-adrenergic receptor
results directly in bronchodilation. Muscarinic antago-
nists also facilitate bronchodilation but work by compet-
ing with acetylcholine for muscarinic receptors [8]. By
inhibiting the action of acetylcholine at receptor sites in
the lung, they indirectly inhibit contraction of airway
smooth muscle. Figure 1[7,8] illustrates the pathways by
which each class of bronchodilator produces smooth
muscle relaxation. b2-adrenergic receptor agonists may
also attenuate cholinergic neurotransmission due to sti-
mulation of b2-adrenergic receptors on parasympathetic
ganglia [9,10].
b2-agonists are widely used in the management of
COPD, either alone or in combination with other
bronchodilators, corticosteroids, or both. Short-acting
b2-agonists (SABAs) were the first agents of the class to
become available for the treatment of COPD. LABAs
with a 12-hour duration of action were subsequently
introduced in the late 1990s, following positive experi-
ence in asthma [11], providing improvements in bronch-
odilator efficacy and patient outcomes compared with
SABAs which have a duration of action of only
4-6 hours [12]. The currently available SABAs and
LABAs are summarized in Table 1[1,13-18].
Current position in management guidelines
SABAs such as salbutamol (albuterol), terbutaline, pir-
buterol or fenoterol and/or short-acting muscarinic
antagonists (SAMAs) such as ipratropium bromide or
oxitropium bromide are recommended as rescue medi-
cation for all severities of COPD to relieve acute symp-
toms of bronchospasm. For patients with Stage II
(moderate) or more severe COPD, regular treatment
with a twice-daily LABA such as formoterol or salme-
terol, or a long-acting muscarinic antagonist (LAMA)
such as tiotropium, is more effective and convenient
than treatment with the shorter-acting agents [1]. As
symptoms progress, combining bronchodilators from
different classes is recommended to improve efficacy.
Figure 1 Indirect and direct relaxation of smooth muscle. Muscarinic antagonists (X) block M3 receptors to prevent binding of acetylcholine
(ACh), indirectly stimulating smooth muscle relaxation via inhibition of bronchoconstriction. b2-agonists interact with b2 receptors (b2R) to
activate coupling of the stimulatory G protein (Gs) with adenylcyclase (AC). This leads to enhanced production of cyclic adenosine
monophosphate (cAMP) which activates protein kinase A (PKA) and results in smooth muscle relaxation. b2-agonists may also interact with
presynaptic b2Rs at parasympathetic ganglia, modulating parasympathetic neurotransmission.
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Inhaled corticosteroids may be added to bronchodilator
treatment in patients with severe COPD and a history of
repeated exacerbations.
No one long-acting bronchodilator is recommended
over another in management guidelines [1], because few
studies have specifically compared different LABAs
[19,20]. In addition, studies comparing LABAs with
LAMAs have not been designed or powered to answer
this clinical question to date, providing inconclusive
results [21-23]. The choice therefore depends on avail-
ability and the response of the individual patient [1].
Inhaled therapy is preferred to oral therapy, in light of
the greater risk of systemic side effects with oral beta-
agonists and the unfavorable safety profile of oral
methylxanthines.
Recently, there has been extensive research into the
efficacy and safety of available twice-daily LABAs, as
well as the development of new long-acting b2-agonists
which have the potential for once-daily use [6]. This
paper focuses on the current and future role of LABAs
in COPD management. The efficacy and safety of cur-
rently available LABAs is reviewed, and their limitations
considered. Articles were identified using a PubMed
search including search terms for all currently available
LABAs (salmeterol, formoterol, arformoterol), b2-ago-
nists, efficacy, safety and chronic obstructive pulmonary
disease/COPD. This is followed by the authors’ views on
the ideal criteria for a new LABA for COPD, and a dis-
cussion of the extent to which novel LABAs, currently
being developed, may meet these criteria.
Clinical efficacy
Efficacy in COPD has traditionally been assessed pri-
marily through impact on lung function measured by
spirometry. However, to adequately understand the
impact of a medication, outcomes of importance to the
patient including symptoms and quality of life must also
be taken into account [24]. The following section
reviews efficacy by endpoint to assess how far salmeterol
and formoterol address the need to improve lung func-
tion, symptoms, exercise endurance, quality of life and
exacerbations in patients with COPD. A summary is
provided in Table 2 [1,25-31].
Lung function
Formoterol and salmeterol have both demonstrated sig-
nificant improvements in lung function [12,26,27,29-51].
Improvements in pre-bronchodilator forced expiratory
volume in 1 second (FEV1) ranged from 50-90 mL com-
pared with placebo [26,30,36,40,49]. Bronchodilation
was rapid in onset with formoterol [34], although salme-
terol had an onset of action slower than salbutamol or
ipratropium bromide [44].
Improvements in lung function were sustained in stu-
dies of 3 months to 3 years’ duration when twice-daily
LABAs were used as maintenance therapy
[28-31,46,48,51,52]. Some studies have suggested there
may be a decline in bronchodilator efficacy over time
with salmeterol [53,54]; over 6 months, significant
declines in peak forced vital capacity (FVC) relative to
placebo (-83 mL, p < 0.05), but not FEV1 (-12 mL),
were observed with salmeterol [53]. Other studies have
also suggested a partial loss of bronchodilator efficacy of
formoterol over time. For example, the initial improve-
ment in mean trough FEV1 (95% confidence interval
[CI]) with formoterol 12 μg compared with placebo
declined from 110 ml (90-130) after Day 1 to 70 mL
(40-100) at Week 12 and to 50 ml (10-90) at Week 52
[55]. Moreover, there appears to be a partial decline in
the integrated 12-hour improvement in FEV1 following
the morning dose of formoterol 24 μg from 3 to
12 months of twice-daily therapy [46]. However, no
Table 1 SABAs and LABAs commonly used in COPD
Drug Dose delivered by
inhaler (μg)
Other formulations Recommended dose Duration of action
(hours)
Onset of
action
Short-acting
Salbutamol
(albuterol)
100, 200 (MDI & DPI) Solution for nebulizer; oral (syrup, tablets);
vials for injection
200 μg up to 4 times
daily
4-6 5 mins
Terbutaline 400, 500 (DPI) 500 μg up to 4 times
daily
4-6 30 mins
Long-acting
Formoterol 4.5-12 (MDI & DPI) Solution for nebulizer (20 μg/2 mL) 12 μg twice daily
(Aerolizer/Easyhaler
9 μg† twice daily
(Turbuhaler)
20 μg twice daily
(Nebulizer)
12+ <5 mins*
Arformoterol Solution for nebulizer (15 μg/2 mL) 15 μg twice daily 12+ 6.7 mins*
Salmeterol 25-50 (MDI & DPI) 50 μg twice daily 12+ 2 hours**
DPI, dry powder inhaler; MDI, metered dose inhaler * mean FEV1 increase of 15%; ** mean FEV1 increase of 12% or more and at least 200 mL;
† delivered dose
(equivalent to 12 μg metered dose)
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evidence of clinically meaningful tolerance has been
demonstrated in pooled or meta-analyses of salmeterol
[56,57].
Further, in a post-hoc analysis from the 3-year
Towards a Revolution in COPD Health (TORCH) study,
salmeterol reduced the rate of decline in lung function
by 13 mL/year compared with placebo (p = 0.003),
which was not statistically different from the reduction
in the rate of decline by salmeterol in combination with
the inhaled corticosteroid fluticasone propionate [58].
Formoterol and salmeterol have demonstrated similar
or greater improvements in lung function compared
with ipratropium bromide [26,29,39,44,45] and signifi-
cantly greater improvements compared with theophyl-
line [35,46,59], but appear to be less effective than
tiotropium [21,60].
Symptom control
Numerous tools and questionnaires have been devel-
oped to assess respiratory symptoms in COPD ranging
from patient rating of symptoms on diary cards, to vali-
dated scales such as the Transition Dyspnea Index
(TDI) and Borg scale of perceived dyspnea, for which
minimal clinically important differences (MCID) have
been established [61-63].
Both formoterol and salmeterol have demonstrated
significant improvement compared with placebo in diary
card symptom scores including breathlessness, together
with significant reductions in the requirement for rescue
medication [12,23,27,29,30,32,36,37,40,48,50,51].
Improvements in symptoms were generally similar
[26,27,46] or greater [29,59] with formoterol and salme-
terol than with ipratropium bromide and theophylline.
Fewer studies have included the TDI instrument, and
these have yielded inconsistent results [21,26,32,33,40,43].
Formoterol 18 μg twice daily, but not 4.5 μg or 9 μg twice
daily via the Turbuhaler, significantly improved TDI by
1.15 units compared with placebo (1.77 vs 0.62 units; p =
0.002) [32], achieving the MCID (≥1 unit) for this instru-
ment. Similarly, nebulized arformoterol (the active (R,R)-
enantiomer of formoterol) 25 μg and 50 μg but not 15 μg
twice daily significantly improved TDI (1.08 and 1.04 units
vs placebo respectively) [33]. In contrast, salmeterol has
not achieved the MCID for TDI in clinical studies
[21,26,33,40,43]. Donohue et al [21] found that only 35%
of patients receiving salmeterol achieved the MCID (p =
ns vs placebo), compared with 42% receiving the LAMA
tiotropium (p < 0.01 vs placebo).
Exercise tolerance
There are fewer studies investigating the effect of LABAs
on exercise tolerance. Two 12-week studies found no sig-
nificant difference in distance covered in the incremental
shuttle walking test with formoterol 18 μg twice daily via
Turbuhaler compared with placebo [32,51]. Similarly,
studies with salmeterol show inconsistent effects on
walking tests compared with placebo [12,39,42,64]. How-
ever, in constant (submaximal) work rate exercise endur-
ance tests (considered to be more responsive to the effect
of pharmacotherapy) [63], significant improvements in
exercise tolerance have been demonstrated for formo-
terol and salmeterol, accompanied by improvements in
dynamic hyperinflation (exercise-induced air trapping
which is a significant contributor to exercise limitation
due to intolerable dyspnea) [65,66]. For example, in cycle
tests performed at 75% of peak work rate, salmeterol sig-
nificantly prolonged exercise time compared with pla-
cebo (6.0 ± 0.8 vs 4.5 ± 0.8 minutes, p < 0.05), although
this fell just short of the 1.75 minute MCID proposed by
Casaburi [67].
Data with active comparators are limited, but small
studies have found similar improvements in exercise
endurance and dyspnea ratings during submaximal or
progressive exercise tests between twice-daily LABAs
and ipratropium bromide [68-70].
Health-related quality of life
In the majority of studies, significant improvements in
health-related quality of life as measured by the St.
George’s Respiratory Questionnaire (SGRQ) have been
demonstrated with formoterol compared with placebo
[23,29-31,46] and with salmeterol compared with pla-
cebo [33,36,48,71] although other studies have failed to
demonstrate a significant effect on quality of life
[21,40,43,51].
In some [29,30,48,71], but not all [23,28,31,33,36] stu-
dies, improvements compared with placebo exceeded
the MCID of 4 units for the SGRQ [72]. Although
Table 2 Summary of clinical efficacy for currently available b2-agonists in COPD
Improvement in outcome
Duration of action (hours)1 Lung function Breathlessness Exercise endurance* Quality of life Exacerbations
Salbutamol (albuterol) 4-6 ✓1,25 ✓1,25 ✓1,25 NA NA
Salmeterol ≥12 ✓✓1,25-27 ✓25-27 ✓1,25 ✓(✓‡)1,25-28 ✓✓1,25,26,28
Formoterol ≥12 ✓✓1,25,29 ✓✓25,29 ✓1,25 ✓✓1,25,29 ✓†1,25,29-31
✓ evidence of effectiveness; ✓✓ evidence of effectiveness over SABA or SAMA; *Outcome demonstrated by all bronchodilators, lack of evidence of significant
differences between them; † equivocal evidence depending on formulation; ‡evidence of numerical improvements over shorter acting comparator; NA =
evidence not available
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improvements in health-related quality of life with for-
moterol and salmeterol were at least as good as those
with ipratropium bromide [26,27,29] and theophylline
[59], overall, a meta-analysis found that LABAs pro-
duced a mean change from baseline of 3.36 units in
SGRQ [73], falling short of the MCID for this instru-
ment. Similarly, in a responder analysis of a 6-month
study, only 42% of patients receiving salmeterol achieved
the MCID for health-related quality of life, compared
with 40% for placebo (p = ns) and 51% receiving tiotro-
pium (p < 0.05 vs salmeterol) [21].
Exacerbations
Exacerbations contribute greatly to the increased mor-
bidity and diminished health-related quality of life of
COPD patients [74]. However, there has been a lack of
a consistent and widely accepted definition with which
to evaluate and compare the efficacy of therapeutic
interventions on this outcome [75]. Definitions of, and
methods for counting, COPD exacerbations vary across
studies, and statisticians disagree as to the most appro-
priate statistical method for analysis [76,77]. Thus, the
results of clinical studies must be interpreted with
caution.
To date, clinical studies have not been specifically
designed to investigate the effect of formoterol on
exacerbations, and no significant benefit on moderate to
severe exacerbations has been demonstrated
[23,30,31,78]. Salmeterol has more consistently demon-
strated a significant effect on COPD exacerbation rate,
which may reflect the study designs used [57]. The 3-year
TORCH study found that salmeterol monotherapy
reduced the annual rate of COPD exacerbations (requir-
ing oral corticosteroids and/or antibiotics and/or hospita-
lization) by 15% compared with placebo (p < 0.001),
although the greatest reductions were observed in the
combination salmeterol/fluticasone propionate arm (25%
annual reduction compared with placebo, p < 0.001) [28].
In a meta-analysis of 14 randomized clinical trials
involving more than 6,400 patients, LABAs (salmeterol
or formoterol) significantly reduced exacerbations
requiring study withdrawal or hospitalization compared
with placebo, with a relative risk of 0.78 (95% CI, 0.67-
0.91) [73]. Hospitalizations tend to be relatively rare
events and there may be large variability in the criteria
applied by different physicians for hospitalizing a patient
for an exacerbation, so this result is difficult to interpret.
However, it is interesting to note that the use of ICS
was not associated with a further risk reduction [73]. In
a more recent meta-analysis of 23 randomized con-
trolled trials of twice-daily LABAs (16 salmeterol vs pla-
cebo, four formoterol vs placebo, three salmeterol vs
tiotropium and one formoterol vs tiotropium), LABAs
significantly reduced the risk of an exacerbation
compared with placebo (odds ratio [OR] 0.84; 95% CI,
0.76-0.92), whereas tiotropium significantly reduced the
exacerbation risk compared with a LABA (OR 0.82; 95%
CI, 0.72-0.93) [79]. A LABA-ICS combination tended to
reduce the risk of an exacerbation more than a LABA
alone, although this did not reach statistical significance
(OR 0.90; 95% CI, 0.80-1.01).
Efficacy summary
In summary, evidence to date suggests that both formo-
terol and salmeterol provide significant improvements in
lung function, symptoms including dyspnea, and health-
related quality of life. However, for the latter two end-
points, not all patients appear to achieve clinically
meaningful improvements, and improvements were
lower than those achieved with the once-daily LAMA
tiotropium. Studies using the sensitive measure of sub-
maximal exercise testing suggest there is a beneficial
effect on exercise tolerance, although data are limited in
this area. There are few definitive studies investigating
the effect of treatment on exacerbations and results
should be interpreted with caution, but suggest a signifi-
cant effect, at least for salmeterol.
Given the general trend for twice-daily LABAs to pro-
vide improved lung function and more consistent symp-
tom control compared with shorter-acting comparators
(Table 2), one could argue that a longer duration of
action is desirable in COPD [80]. The extension of this
argument is that efficacy could be further improved by
the introduction of a once-daily LABA.
Clinical safety
There is clear consensus with regard to the central role
of inhaled bronchodilators as the standard of care in
COPD patients. However, recent concerns have been
raised suggesting that LABA use could lead to an
increased risk of respiratory death in patients with
asthma. This was initiated by the results of the Salme-
terol Multicenter Asthma Research Trial (SMART),
which investigated the safety of adding salmeterol to
usual asthma treatment in patients not already receiving
a LABA; it was stopped following an interim analysis in
26,355 patients because of a small but significant
increase in the number of asthma-related deaths in the
salmeterol group [81]. These results raised significant
doubts about the safety of LABA monotherapy in
patients with asthma. Recent editorials have recom-
mended that physicians should continue to use LABAs
to treat asthma, but only when combined with appropri-
ate doses of inhaled corticosteroids [82,83].
In COPD there are no restrictions on LABA use as
monotherapy. COPD is a distinct disease from asthma,
although there is some degree of overlap, with an esti-
mated 10-50% of COPD patients having concomitant
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asthma. This wide variation in reported prevalence may
relate to differences in diagnostic criteria [84,85]. An
overlap in symptoms, together with the lack of validated
discriminatory biomarkers, can make differential diagno-
sis difficult. The major distinguishing features between
the two diseases are clinical: in general, COPD occurs
later in life, with slowly progressive symptoms during
exercise and is associated with a history of smoking or
exposure to noxious gases and particulates. Asthma is
likely to present early in life (often in childhood) and be
associated with symptoms which vary from day to day,
often at night or in the early morning; subjects often
have a history of asthma in their family and airflow lim-
itation tends to be more reversible than in COPD [1,86].
It is important to recognize that COPD, in most cases,
is associated with significant, albeit never complete,
reversibility [87-89] at one time or another. Therefore, it
is not appropriate as is sometimes done, to refer to
COPD patients who exhibit significant reversibility in
response to a bronchodilator as having an ‘asthmatic’
component or ‘mixed disease’. Indeed, the fact that
most COPD patients respond significantly to a broncho-
dilator provides the major rationale for the recommen-
dation of bronchodilators as the mainstay of therapy for
COPD.
LABA monotherapy in COPD is not associated with
increased risk of respiratory mortality. A meta-analysis
performed in 2006 [90], suggested that b2-agonists were
associated with an increased rate of respiratory deaths
compared with placebo, and a 2-fold greater risk of
severe exacerbations compared with muscarinic antago-
nists. However, this meta-analysis did not include the
large dataset provided by the TORCH study [28].
TORCH found no increased risk of mortality with sal-
meterol monotherapy. Indeed, factorial analyses [91,92]
have suggested the numerical mortality benefit observed
with the combination (17.5% reduction in risk of death,
p = 0.052) might be driven by the LABA component
(Table 3) [91]. Further, a recent meta-analysis of 27 stu-
dies found no significant difference between LABA and
placebo in terms of risk of respiratory death (relative
risk 1.09 [95%, CI 0.45-2.64]) [73]. These results were
confirmed in a more recent meta-analysis of 23 trials
that also failed to find any increased mortality risk com-
paring a LABA with placebo (odds ratio 0.95 [95% CI,
0.71-1.27]) [79].
Clinical studies have demonstrated that both formo-
terol and salmeterol are well tolerated, over periods of
at least a year [28,30,31,36,48,78]. Commonly occurring
LABA class effects include palpitations, headache and
tremor, which may limit the dose that can be tolerated,
especially in some older patients [1]. Cardiovascular side
effects are also possible in susceptible patients [93], and
there is some risk associated with the use of b2-agonists
in patients with COPD and concomitant cardiac dis-
eases, particularly chronic heart failure [94,95].
Chronic heart failure is a frequent comorbidity in
patients with COPD. Cazzola et al [96] reported that
COPD patients in Italy were at increased risk of chronic
heart failure compared with the general population
(7.9% compared with 2%), while in a Scottish study,
11.9% patients with COPD also had chronic heart failure
[97]. Older individuals were at even higher risk in both
studies. Moreover, heart failure may be under-diagnosed
in COPD due to diagnostic confusion between the two
diseases [98]. Research by Au et al. [99,100] indicates a
strong trend towards a dose-response relationship of
increased hospitalization and death, due to heart failure
in patients with underlying heart failure who received
increasing amounts of b2-agonist. Thus it is important
that physicians should exercise caution in using high
doses of b2-agonists in such patients.
However, studies specifically investigating safety have
demonstrated that formoterol and salmeterol have good
cardiovascular safety profiles [101,102]. Further, studies
with formoterol found a similar profile irrespective of
device or formulation [103,104]. In a large cohort of
patients with no or stable cardiac comorbidities, the
proportion of patients with treatment-emergent atrial
tachycardia ranged from 27%-32% and was non-signifi-
cantly higher, by 2%-5% (p = 0.70), in patients receiving
salmeterol or arformoterol compared with placebo;
more serious arrhythmias did not increase, nor did
mean heart rate [105].
Improving b2-agonists
Formoterol and salmeterol have acceptable benefit:risk
profiles in the treatment of COPD; however, both have
their limitations. For example, both formoterol and sal-
meterol have 12-hour durations of action and are
approved for twice-daily dosing. The longer duration of
bronchodilation of twice-daily LABAs compared with
SABAs appears to be associated not only with improved
lung function but also with more consistent efficacy in
symptomatic endpoints, such as breathlessness and qual-
ity of life (Table 2). Evidence also indicates that LAMAs
with a 24-hour duration of action have additional bene-
fits in comparison with shorter acting SAMAs [106].
This suggests that sustained bronchodilation is desirable
for a bronchodilator [80] and that a LABA with a 24-
hour duration of action could provide further improve-
ments in efficacy compared with twice-daily LABAs. In
addition, patient adherence to treatment plans is a
major obstacle to successful COPD management, espe-
cially since it is likely that patients will also be on a
range of medications for comorbidities. Simplified dos-
ing regimens are known to improve compliance [107],
so that once-daily dosing is an important strategy to
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improve compliance and is a regimen preferred by most
patients [6].
Fast onset of action is a significant feature of broncho-
dilators and may be beneficial for patients with COPD.
Rapid relief of symptoms which patients can feel from
the first dose provides reassurance of effect, and is likely
to improve compliance with the medication [108,109].
When administered in the morning, the fast onset of
action of bronchodilators is also advantageous, since
COPD symptoms and patients’ ability to perform daily
activities appear to be worst in the morning [110].
While formoterol has an onset of action similar to sal-
butamol, salmeterol may not produce a significant
increase in bronchodilation for as long as 2 hours fol-
lowing the dose.
For COPD patients, bronchodilator medication is a
chronic maintenance therapy, and it is desirable that
efficacy should be maintained over time. As discussed
above there is some evidence of loss of bronchodilator
effectiveness over time with b2-agonists, as demon-
strated by Tsagaraki et al. [54], Donohue et al. [21],
Dahl et al. [55] and Rossi et al. [46] although the clinical
significance of these changes remains unclear.
Studies to date with twice-daily LABAs indicate that a
minority of patients achieve clinically relevant improve-
ments in dyspnea or health-related quality of life, based
on current validated thresholds [21,73]. Data with cur-
rent twice-daily LABAs in terms of preventing COPD
exacerbations are mixed, with some studies showing no
effect [30,31,48]. However, evidence from large datasets
such as TORCH and pooled analyses reviewed above
support a relatively modest reduction in the rate of
moderate and severe exacerbations [28,73,79].
Improvements in these areas are desirable, but it is
also essential that a new LABA has a comparable, if not
better, safety profile compared with twice-daily LABAs.
LABAs are associated with known class effects, the most
significant being related to cardiac safety [1]. While the
balance of evidence (as reviewed above) indicates that
current LABAs are well tolerated, it is important that
any new entry to the market ensures that potential car-
diac effects are minimized, especially taking into account
that COPD patients are often older and may have cardi-
ovascular comorbidities.
Finally, consideration should be given to the delivery
of any new molecule, ensuring the inhaler device is
appropriate to the COPD patient. Many COPD patients
have difficulty in using metered-dose inhalers so dry
powder inhalers that are of low resistance, relatively
insensitive to changes in airflow and can be used irre-
spective of inspiratory flow rate may be beneficial [111].
Soft-mist inhalers are also less technique-dependent
than metered-dose inhalers [112], and may hold promise
for future delivery of LABAs alone or in combination
with other agents.
Ultra-LABAs in development for use in COPD
’Ultra-LABA’ is a term already in use to describe the
class of once-daily LABAs in development [6,113].
Ultra-LABAs providing not only once-daily dosing but
also improvements in the range of criteria outlined
above would represent an advance on currently available
LABAs, and an alternative to existing once-daily
bronchodilators for the treatment of COPD. Tiotropium,
the only once-daily inhaled bronchodilator currently
available, is a LAMA that significantly improves lung
function, increases exercise capacity and improves effec-
tiveness of pulmonary rehabilitation, improves health
status, and reduces exacerbations [1,79]. Although a
four-year study of tiotropium on a background of usual
therapy did not reduce the rate of decline in lung func-
tion [114], post-hoc analyses did demonstrate a modest,
but significant, reduction in the rate of decline in lung
function with tiotropium compared with placebo in
patients not on other maintenance drugs [114,115].
However, tiotropium is relatively slow in onset of action
Table 3 Effects of treatment with salmeterol and fluticasone on mortality
Main effect*
Factor Placebo
(A)
Salmeterol
(B)
Fluticasone
(C)
Salmeterol plus
fluticasone (D)
Salmeterol received Fluticasone received
Yes (B+D) No (A+C) Yes (C+D) No (A+B)
No. of subjects 1,524 1,521 1,534 1,533 3,054 3,058 3,067 3,045
No. of deaths 231 205 246 193 398 477 439 436
Probability of deaths
at 3 years (%)
15.2 13.5 16.0 12.6 13.0 15.6 14.3 14.3
Hazard ratio (95%
confidence interval)
0.81 (0.70-0.94) 1.00 (0.87-1.15)
Chi-square 8.20 0.00
P value 0.004 0.99
*Data were analyzed according to a factorial design to estimate the main effect of each drug with adjustment for the other
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and is associated with anticholinergic side effects, such
as dry mouth (most commonly) and urinary retention
(rarely) [1].
Ultimately, the choice of one agent over another as
monotherapy in individual COPD patients will depend
on a number of factors, including the expected side
effects of each class of drugs, data on comparative effi-
cacy with respect to onset, magnitude and duration of
action, preference for the delivery device used and cost.
A number of novel LABAs with once-daily profiles are
in development [6]. Here, we summarize the data avail-
able to date for the most promising of these.
Indacaterol, a novel inhaled ultra-LABA, has recently
been approved in Europe for the treatment of COPD
and is the first ultra-LABA to be launched in this
region. Preclinical and Phase II studies indicated that
indacaterol has a 24-hour duration of bronchodilation
with fast onset of action, a good cardiovascular safety
profile and no antagonism of the effect of rescue medi-
cation [22,116-121]. Further, Bauwens et al. [117]
included doses approved for registration (150 and 300
μg) and demonstrated that the bronchodilator efficacy
of indacaterol (150, 300 and 600 μg) at 24 hours post-
dose was at least as good as formoterol 12 μg twice
daily (Figure 2[117]).
It has been hypothesized that indacaterol’s long dura-
tion of action may relate to its high affinity for the lipid
raft domain of the cell membrane [122] (cholesterol-
enriched microdomains of the lipid membrane, where
b2-receptors are held together in close contact with sig-
naling molecules and effectors) [123].
A number of placebo- and active-controlled Phase III
studies in COPD have been completed or are ongoing
[55,124-129]. Indacaterol 150 μg once daily significantly
improved trough FEV1 at 12 weeks by 130-180 mL com-
pared with placebo (p < 0.001) [125,127-129] while the
300 μg dose provided improvements of 170-180 mL
(p < 0.001) [55,127,129], sustained over 1 year [55,129].
Both doses were significantly more effective than open-
label tiotropium (p ≤ 0.01) [127] while in further studies,
the 150 μg dose was significantly more effective than
salmeterol 50 μg twice daily (p < 0.001) [128], and the
300 μg dose was significantly more effective than formo-
terol 12 μg twice daily (p < 0.05) [55].
Patient outcomes were also improved: indacaterol 150
and 300 μg significantly improved dyspnea as measured
by TDI to a clinically relevant degree in a six month
study (≥1 unit, p < 0.001) [127] with similar results
achieved for indacaterol 300 μg throughout a 12 month
study (1.00-1.32 unit improvement vs placebo, p <
0.001) [55]. In addition, indacaterol 150 and 300 μg
were found to be at least as effective as open-label tio-
tropium in improving clinical outcomes over a 26-week
period [127]. Indacaterol 150 and 300 μg also
significantly reduced dyspnea compared with salmeterol
and formoterol (p < 0.05) [55,128], and significantly
reduced rescue medication use compared with tiotro-
pium and salmeterol (p < 0.05) [127,128]. Patients
reported significant improvements in health-related
quality of life as measured by SGRQ for both doses
compared with placebo in 6 month studies (p ≤ 0.01)
[127,128] with the 150 μg dose achieving a clinically
relevant improvement of 5 units versus placebo at 26
weeks in one study (p < 0.001) [128]. Further, indaca-
terol 300 μg achieved significant, clinically relevant
improvements over one year (-4.7 units improvement at
Week 52, p < 0.001 vs placebo) [55]. In studies of up to
one year, indacaterol was well tolerated with an accepta-
ble safety profile, including cardiovascular safety, similar
to placebo, and comparable to tiotropium and formo-
terol [55,127,128].
Olodaterol (BI-1744 CL) is in a late stage of develop-
ment. Preclinical studies with olodaterol suggested a
potential for once-daily dosing in humans, along with a
rapid onset of action and a favorable safety profile
[130,131]. Phase III studies are based on doses of 5 and
10 μg once daily, delivered via the Respimat® device
[124].
Carmoterol has demonstrated long duration of activity
in patients with COPD [132,133], with no tolerance
observed over two weeks of treatment [134]. In a Phase
II study, the 2 μg and 4 μg doses of carmoterol given
once daily resulted in significant bronchodilation over
24 hours compared to placebo and comparable to that
obtained with salmeterol 50 μg twice daily in patients
with COPD [135]. No cardiac safety concerns were
reported at doses less than 16 μg in healthy volunteers
[136], while in patients with COPD initial data also sug-
gests it has a good safety profile and is well tolerated
[137].
Vilanterol trifenatate (GW642444M) [138,139] has
also completed Phase II clinical trials [4,124]. In a four-
week dose-ranging study involving 605 subjects, all
doses (3, 6.25, 12.5, 25 and 50 μg once daily) achieved
statistically significant increases in lung function (trough
FEV1) compared to placebo (p < 0.05), with the two
highest doses exceeding a predefined threshold of 130
mL increase in FEV1. Improvements in lung function
were sustained over 24 hours. Vilanterol trifenatate was
well tolerated at all doses and the frequency of adverse
events was comparable to placebo [139].
PF-00610355 has been investigated in Phase I studies
in healthy male subjects. A single dose of PF-00610355
450 μg had a superior duration of action as measured
by specific airway conductance (sGAW) compared with
placebo (16.4 hours longer) and salmeterol (9.8 hours
longer) [140]. PF-00610355 was also well tolerated over
14 days within the anticipated clinical dose range (≤600
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μg) [141]. Further studies will be needed to confirm if
this drug has a 24-hour duration of bronchodilator
action and is suitable for once-daily dosing.
Potential impact of ultra-LABAs on COPD management as
monotherapy and in combination
It could be hypothesized that a longer duration of
bronchodilation with an ultra-LABA may be associated
with superior and more consistent efficacy over a range
of endpoints than is achieved with a twice-daily LABA.
Furthermore, compared with complicated or multiple
treatment regimens, simplified (once-daily) treatment
regimens represent a significant convenience benefit and
increase the likelihood of compliance with treatment -
as does fast onset of action and a favorable safety pro-
file. Together, these benefits could lead to improved
overall clinical outcomes in COPD patients [6], and
might help compliance with GOLD guidelines.
Based on the results of studies combining currently
available LABAs and LAMAs [23,50,142-145], signifi-
cantly greater improvements in lung function and symp-
toms can be achieved with a twice-daily LABA in
combination with a LAMA compared with tiotropium
used alone. Further, initial data from a single study sug-
gests LABA/LAMA combinations may provide superior
bronchodilator efficacy compared with LABA/ICS, at
least in moderate COPD [146]; however, this was a
short-term (6 weeks) study and did not assess possible
differences in patient-reported outcomes. Longer-term
studies are required with sufficient power to assess the
relative efficacy of such combinations on quality of life
and exacerbations. The introduction of ultra-LABAs is
likely to further improve outcomes for patients, when
used in combination with a LAMA. Current opinion is
that it will be advantageous to develop inhalers contain-
ing combinations of two or more classes of once-daily
long-acting bronchodilator drugs, in an attempt to sim-
plify treatment regimens as much as possible [6]. Several
ultra-LABA/LAMA combinations are in development,
including QVA149 (indacaterol + NVA237 [glycopyrro-
late]) [147,148] and vilanterol trifenatate/darotropium
bromide [124].
As COPD progresses, patients with frequent exacerba-
tions may require ‘triple therapy’ with a LAMA, LABA
and an ICS. Evidence to date indicates that ICS/LABA
in combination with tiotropium improves lung function,
Figure 2 Adjusted mean (±95% CI) standardized 24 hour trough FEV1 for indacaterol 150, 300 and 600 μg compared with placebo
and formoterol 12 μg. ANCOVA for treatment contrasts: **p < 0.001 vs. placebo; †p < 0.01 and ‡p < 0.05 vs. formoterol; ¶p < 0.05 vs.
indacaterol 150 μg.
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symptoms and health status, and reduces the risk of
hospitalizations compared with tiotropium alone in
patients with COPD [149-151]. These findings lend sup-
port to the concept that combining different classes of
drugs with different mechanisms such as ultra-LABAs
and once-daily LAMAs and ICS will further improve
efficacy, and represent an important step towards the
goal of optimal control for COPD patients.
Conclusions
Long-acting bronchodilators are fundamental to the
management of COPD; however, many patients remain
symptomatic despite their use. Twice-daily LABAs sal-
meterol and formoterol provide some improvements in
clinical outcomes compared with placebo and, although
there are known class effects, have a favorable safety pro-
file. However, in studies including validated instruments
to measure dyspnea and health-related quality of life, not
all patients achieve clinically meaningful improvements.
Thus, there is still an unmet need, particularly to
improve symptoms, in many COPD patients. A range of
features can be identified that could be considered to be
criteria for a new LABA to fulfil. In particular, longer
duration of action than 12 hours appears to be asso-
ciated with improved, more consistent benefits across a
range of outcomes. New ultra-LABAs have the potential
to improve outcomes for COPD patients, both alone
(providing an alternative to the only once-daily muscari-
nic antagonist bronchodilator currently available) or in
combination. There are already promising data for inda-
caterol, which is likely to be the first ultra-LABA to be
available for the treatment of COPD.
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